1-Boc-3-hydroxypiperidine → 1-(tert-Butoxycarbonyl)-3-[(4'-chlorobiphenyl-4-yl)methoxy]piperidine
반응식
[C:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][CH2:11][CH:10]([OH:14])[CH2:9]1)=[O:7])([CH3:4])([CH3:3])[CH3:2].[Cl:15][C:16]1[CH:21]=[CH:20][C:19]([C:22]2[CH:27]=[CH:26][C:25]([CH2:28]Cl)=[CH:24][CH:23]=2)=[CH:18][CH:17]=1>>[C:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][CH2:11][CH:10]([O:14][CH2:28][C:25]2[CH:24]=[CH:23][C:22]([C:19]3[CH:20]=[CH:21][C:16]([Cl:15])=[CH:17][CH:18]=3)=[CH:27][CH:26]=2)[CH2:9]1)=[O:7])([CH3:4])([CH3:2])[CH3:3]참가 물질
3
실험 절차
Using 1-(tert-butoxycarbonyl)-3-hydroxypiperidine (403 mg, 2.00 mmol) and 4′-chloro-4-chloromethylbiphenyl (474 mg, 2.00 mmol), the same procedure was followed as in Step 6a of Example 6 to give 672 mg (84%) of the desired compound as a colorless powder.
출처 및 근거
- ORD 기록
- ord-aac6f53a90d446a4aadf87b1adb8ad31
- 출처 데이터셋
- uspto-grants-2011_03